Skip Header

You are using a version of Internet Explorer that may not display all features of this website. Please upgrade to a modern browser.

1 - 25 of 206 results for author:"Nakagawa K." in Literature citations

Page of 9 | Next »

to top of page·  

Results Customize

› Repeat search in UniProtKB (12,986)

CYP2C19 genotype-based phase I studies of a c-Met inhibitor tivantinib in combination with erlotinib, in advanced/metastatic non-small cell lung cancer.

Yamamoto N., Murakami H., Hayashi H., Fujisaka Y., Hirashima T., Takeda K., Satouchi M., Miyoshi K., Akinaga S., Takahashi T. et al.

Br. J. Cancer 109:2803-2809(2013) · Mapped (3)

A phase I, pharmacokinetic and pharmacodynamic study of nimotuzumab in Japanese patients with advanced solid tumors.

Okamoto W., Yoshino T., Takahashi T., Okamoto I., Ueda S., Tsuya A., Boku N., Nishio K., Fukuoka M., Yamamoto N. et al.

Cancer Chemother. Pharmacol. 72:1063-1071(2013) · Mapped (20)

The RASSF6 tumor suppressor protein regulates apoptosis and the cell cycle via MDM2 protein and p53 protein.

Iwasa H., Kudo T., Maimaiti S., Ikeda M., Maruyama J., Nakagawa K., Hata Y.

J. Biol. Chem. 288:30320-30329(2013) · Mapped (49)

Enhancement of in vitro cell motility and invasiveness of human malignant pleural mesothelioma cells through the HIF-1alpha-MUC1 pathway.

Goudarzi H., Iizasa H., Furuhashi M., Nakazawa S., Nakane R., Liang S., Hida Y., Yanagihara K., Kubo T., Nakagawa K. et al.

Cancer Lett. 339:82-92(2013) · Mapped (9)

hypoxia-inducible factors activate CD133 promoter through ETS family transcription factors.

Ohnishi S., Maehara O., Nakagawa K., Kameya A., Otaki K., Fujita H., Higashi R., Takagi K., Asaka M., Sakamoto N. et al.

PLoS ONE 8:e66255-e66255(2013) · Mapped (17)

gamma-Tocotrienol attenuates triglyceride through effect on lipogenic gene expressions in mouse hepatocellular carcinoma Hepa 1-6.

Burdeos G.C., Nakagawa K., Watanabe A., Kimura F., Miyazawa T.

J. Nutr. Sci. Vitaminol. 59:148-151(2013) · Mapped (7)

CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study.

Seto T., Kiura K., Nishio M., Nakagawa K., Maemondo M., Inoue A., Hida T., Yamamoto N., Yoshioka H., Harada M. et al.

Lancet Oncol. 14:590-598(2013) · Mapped (18)

The prognostic significance of vasohibin-1 expression in patients with prostate cancer.

Kosaka T., Miyazaki Y., Miyajima A., Mikami S., Hayashi Y., Tanaka N., Nagata H., Kikuchi E., Nakagawa K., Okada Y. et al.

Br. J. Cancer 108:2123-2129(2013) · Mapped (2)

Critical role of Trib1 in differentiation of tissue-resident M2-like macrophages.

Satoh T., Kidoya H., Naito H., Yamamoto M., Takemura N., Nakagawa K., Yoshioka Y., Morii E., Takakura N., Takeuchi O. et al.

Nature 495:524-528(2013) · Mapped (10)

Rapid response of brain metastasis to crizotinib in a patient with ALK rearrangement-positive non-small-cell lung cancer.

Kaneda H., Okamoto I., Nakagawa K.

J Thorac Oncol 8:e32-3(2013) · Mapped (18)

Yes-associated protein homolog, YAP-1, is involved in the thermotolerance and aging in the nematode Caenorhabditis elegans.

Iwasa H., Maimaiti S., Kuroyanagi H., Kawano S., Inami K., Timalsina S., Ikeda M., Nakagawa K., Hata Y.

Exp. Cell Res. 319:931-945(2013) · Mapped (8)

Sorting nexin 2-mediated membrane trafficking of c-Met contributes to sensitivity of molecular-targeted drugs.

Ogi S., Fujita H., Kashihara M., Yamamoto C., Sonoda K., Okamoto I., Nakagawa K., Ohdo S., Tanaka Y., Kuwano M. et al.

Cancer Sci. 104:573-583(2013) · Mapped (6)

MET amplification as a potential therapeutic target in gastric cancer.

Kawakami H., Okamoto I., Arao T., Okamoto W., Matsumoto K., Taniguchi H., Kuwata K., Yamaguchi H., Nishio K., Nakagawa K. et al.

Oncotarget 4:9-17(2013) · Mapped (22)

Severe acute interstitial lung disease after crizotinib therapy in a patient with EML4-ALK-positive non-small-cell lung cancer.

Tamiya A., Okamoto I., Miyazaki M., Shimizu S., Kitaichi M., Nakagawa K.

J. Clin. Oncol. 31:e15-7(2013) · Mapped (5)

Cancer susceptibility and embryonic lethality in Mob1a/1b double-mutant mice.

Nishio M., Hamada K., Kawahara K., Sasaki M., Noguchi F., Chiba S., Mizuno K., Suzuki S.O., Dong Y., Tokuda M. et al.

J. Clin. Invest. 122:4505-4518(2012) · Mapped (4)

The combination of mitochondrial low enzyme-activity aldehyde dehydrogenase 2 allele and superoxide dismutase 2 genotypes increases the risk of hypertension in relation to alcohol consumption.

Nakagawa T., Kajiwara A., Saruwatari J., Hamamoto A., Kaku W., Oniki K., Mihara S., Ogata Y., Nakagawa K.

Pharmacogenet. Genomics 23:34-37(2013) · Mapped (11)

Characterization of RSF-1, the Caenorhabditis elegans homolog of the Ras-association domain family protein 1.

Iwasa H., Kuroyanagi H., Maimaiti S., Ikeda M., Nakagawa K., Hata Y.

Exp. Cell Res. 319:1-11(2013) · Mapped (7)

SCN1A IVS5N+5 polymorphism and response to sodium valproate: a multicenter study.

Haerian B.S., Baum L., Tan H.J., Kwan P., Raymond A.A., Saruwatari J., Nakagawa K., Mohamed Z.

Pharmacogenomics 13:1477-1485(2012) · Mapped (7)

The nuclear protein Artemis promotes AMPK activation by stabilizing the LKB1-AMPK complex.

Nakagawa K., Uehata Y., Natsuizaka M., Kohara T., Darmanin S., Asaka M., Takeda H., Kobayashi M.

Biochem. Biophys. Res. Commun. 427:790-795(2012) · Mapped (10)

A novel mass spectrometry-based assay for diagnosis of EML4-ALK-positive non-small cell lung cancer.

Sakai K., Okamoto I., Takezawa K., Hirashima T., Kaneda H., Takeda M., Matsumoto K., Kimura H., Fujita Y., Nakagawa K. et al.

J Thorac Oncol 7:913-918(2012) · Mapped (5)

The prognostic significance of vasohibin-1 expression in patients with upper urinary tract urothelial carcinoma.

Miyazaki Y., Kosaka T., Mikami S., Kikuchi E., Tanaka N., Maeda T., Ishida M., Miyajima A., Nakagawa K., Okada Y. et al.

Clin. Cancer Res. 18:4145-4153(2012) · Mapped (2)

The RASSF3 candidate tumor suppressor induces apoptosis and G1-S cell-cycle arrest via p53.

Kudo T., Ikeda M., Nishikawa M., Yang Z., Ohno K., Nakagawa K., Hata Y.

Cancer Res. 72:2901-2911(2012) · Mapped (50)

A novel acetylation cycle of transcription co-activator Yes-associated protein that is downstream of Hippo pathway is triggered in response to SN2 alkylating agents.

Hata S., Hirayama J., Kajiho H., Nakagawa K., Hata Y., Katada T., Furutani-Seiki M., Nishina H.

J. Biol. Chem. 287:22089-22098(2012) · Mapped (7)

Changes in synovial fluid biochemical markers following arthroscopic surgery in patients with knee osteoarthritis.

Nakajima A., Nakagawa K., Aoki Y., Sonobe M., Shibata Y., Yamazaki M., Murakami M.

Rheumatol. Int. 33:209-214(2013) · Mapped (8)

Hypoxia induces IGFBP3 in esophageal squamous cancer cells through HIF-1alpha-mediated mRNA transcription and continuous protein synthesis.

Natsuizaka M., Naganuma S., Kagawa S., Ohashi S., Ahmadi A., Subramanian H., Chang S., Nakagawa K.J., Ji X., Liebhaber S.A. et al.

FASEB J. 26:2620-2630(2012) · Mapped (26)

to top of page·

Page of 9 | Next »